The invention discloses a novel sorafenib tosylate polycrystalline form A and a preparation method thereof. A DSC spectrum of the crystal form comprises a transition peak at 198.0-207.5 DEG C and a melting decomposition peak at 238.5-247.5 DEG C. The invention also discloses a method for preparing the sorafenib tosylate (I) polycrystalline form A from sorafenib free base and p-toluenesulfonic acid in a mixed solvent of alcohol and water. The method has the advantages of good repeatability, simple operation, high product yield, high purity, and suitability for industrialized productions.